Cancer Cell-Intrinsic PD-1 and Implications in Combinatorial Immunotherapy
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cancer Cell-Intrinsic PD-1 and Implications in Combinatorial Immunotherapy
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 9, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2018-07-30
DOI
10.3389/fimmu.2018.01774
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Predicting and Understanding Cancer Response to Treatment
- (2018) Maurizio Callari et al. DISEASE MARKERS
- IDO expression in breast cancer: an assessment of 281 primary and metastatic cases with comparison to PD-L1
- (2018) Erik A. Dill et al. MODERN PATHOLOGY
- Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion
- (2018) Yiting Wang et al. Frontiers in Pharmacology
- Blockade of Tumor-Expressed PD-1 promotes lung cancer growth
- (2018) Shisuo Du et al. OncoImmunology
- Programmed cell death-1 (PD-1) checkpoint blockade in combination with a mammalian target of rapamycin inhibitor restrains hepatocellular carcinoma growth induced by hepatoma cell-intrinsic PD-1
- (2017) Hui Li et al. HEPATOLOGY
- Rise of PD-L1 expression during metastasis of colorectal cancer: Implications for immunotherapy
- (2017) Huan Bin Wang et al. Journal of Digestive Diseases
- Real-world treatment patterns and outcomes among metastatic cutaneous melanoma patients treated with ipilimumab
- (2017) P. Mohr et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study
- (2017) Elizabeth R Plimack et al. LANCET ONCOLOGY
- Tumor PDCD1LG2 (PD-L2) Expression and the Lymphocytic Reaction to Colorectal Cancer
- (2017) Yohei Masugi et al. Cancer Immunology Research
- PD-L2 expression in colorectal cancer: Independent prognostic effect and targetability by deglycosylation
- (2017) Huanbin Wang et al. OncoImmunology
- Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas
- (2016) Joshua D Campbell et al. NATURE GENETICS
- Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth
- (2015) Sonja Kleffel et al. CELL
- Immune Checkpoint Blockade in Cancer Therapy
- (2015) Michael A. Postow et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
- (2015) Jeffrey S Weber et al. LANCET ONCOLOGY
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- PD-1 as an Immune Modulatory Receptor
- (2014) Sheng Yao et al. CANCER JOURNAL
- Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies
- (2014) G. K. Philips et al. INTERNATIONAL IMMUNOLOGY
- Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
- (2014) Matthew M. Gubin et al. NATURE
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Immune Modulation in Cancer with Antibodies
- (2013) David B. Page et al. Annual Review of Medicine
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- (2013) Omid Hamid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade Enhances T-cell Migration to Tumors by Elevating IFN- Inducible Chemokines
- (2012) W. Peng et al. CANCER RESEARCH
- Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
- (2012) Suzanne L Topalian et al. CURRENT OPINION IN IMMUNOLOGY
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- A roadmap to generate renewable protein binders to the human proteome
- (2011) Karen Colwill et al. NATURE METHODS
- Modulation of T-Cell Activation by Malignant Melanoma Initiating Cells
- (2010) T. Schatton et al. CANCER RESEARCH
- Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+T cell dysfunction in melanoma patients
- (2010) Julien Fourcade et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Blocking TNF-α in mice reduces colorectal carcinogenesis associated with chronic colitis
- (2008) Boryana K. Popivanova et al. JOURNAL OF CLINICAL INVESTIGATION
- Identification of cells initiating human melanomas
- (2008) Tobias Schatton et al. NATURE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More